| Literature DB >> 20394077 |
Magdalena Hagn1, Verena Ebel, Kai Sontheimer, Elisabeth Schwesinger, Oleg Lunov, Thamara Beyer, Dorit Fabricius, Thomas F E Barth, Andreas Viardot, Stephan Stilgenbauer, Julia Hepp, Karin Scharffetter-Kochanek, Thomas Simmet, Bernd Jahrsdörfer.
Abstract
Recently, we reported that IL-21 induces granzyme B (GzmB) and GzmB-dependent apoptosis in malignant CD5(+) B cells from patients with chronic lymphocytic leukemia. Several autoimmune diseases (AD) are associated with enhanced frequencies of CD5(+) B cells. Since AD are also associated with elevated IL-21 and GzmB levels, we postulated a link between CD5(+) B cells, IL-21 and GzmB. Here, we demonstrate that IL-21 and GzmB serum levels are highly correlated in subjects with systemic lupus erythematosus (SLE) and that freshly isolated CD5(+) SLE B cells constitutively express GzmB. IL-21 directly induced GzmB expression and secretion by CD5(+) B cells from several AD and from cord blood in vitro, and the simultaneous presence of BCR stimulation strongly enhanced this process. Furthermore, IL-21 suppressed both viability and expansion of CD5(+) B cells from SLE individuals. In summary, our study may explain the elevated levels of IL-21 and GzmB in SLE and other AD. Moreover, our data suggest that IL-21 may have disease-modifying characteristics by inducing GzmB in CD5(+) B cells and by suppressing their expansion. Our results provide the rationale for further evaluation of the therapeutic potential of IL-21 in certain AD such as SLE.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20394077 DOI: 10.1002/eji.200940113
Source DB: PubMed Journal: Eur J Immunol ISSN: 0014-2980 Impact factor: 5.532